Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:41Neutral
Price Target:
$6.00
▲(33.63% Upside)
Action:Reiterated
Date:07/28/26
The score is primarily constrained by weak financial performance (no revenue, sustained losses, ongoing cash burn, and negative equity), which implies elevated financing and dilution risk. Technicals add only modest support with price above the 20-day average but still below longer-term moving averages. Valuation signals are limited because a negative P/E reflects unprofitable operations and there is no dividend yield provided.
Positive Factors
Proprietary T-cell platform
Tevogen’s core business is a precision T‑cell therapy platform targeting viral infections and cancers. Platform-driven models create durable optionality: multiple candidate programs, partnership or licensing paths, and long-term value capture if clinical/regulatory milestones validate efficacy.
Negative Factors
No revenue
The absence of commercial revenue leaves Tevogen entirely dependent on external financing until a product is commercialized. Over the medium term this raises dilution and execution risk, as sustained operations require successful clinical outcomes, partnerships, or recurrent capital raises.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary T-cell platform
Tevogen’s core business is a precision T‑cell therapy platform targeting viral infections and cancers. Platform-driven models create durable optionality: multiple candidate programs, partnership or licensing paths, and long-term value capture if clinical/regulatory milestones validate efficacy.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.24M
Dividend YieldN/A
Average Volume (3M)557.82K
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue GrowthN/A
EPS Growth38.95%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.84
Shares Outstanding6,416,540
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precisio...
How the Company Makes Money
null...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
14
Very Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -144.84K | 0.00 | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -20.83M | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
| Net Income | -21.35M | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | ||||||
| Total Assets | 4.92M | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 692.30K | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.07M | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 14.76M | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -9.84M | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.82M | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -11.75M | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 10.54M | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Negative
4.49
Price Trends
7.23
Negative
6.97
Negative
12.88
Negative
Market Momentum
0.03
Negative
53.24
Neutral
79.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Negative. The current price of 4.49 is below the 20-day moving average (MA) of 5.39, below the 50-day MA of 7.23, and below the 200-day MA of 12.88, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 53.24 is Neutral, neither overbought nor oversold. The STOCH value of 79.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $384.77M | -2.92 | -50.68% | ― | -12.37% | 19.59% | |
53 Neutral | $638.93M | -11.22 | -60.73% | ― | -78.29% | 54.16% | |
52 Neutral | $678.43M | -16.43 | -147.78% | ― | ― | -16.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $149.53M | -1.56 | -30.90% | ― | ― | 10.70% | |
41 Neutral | $45.24M | -1.21 | 241.39% | ― | ― | 38.95% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
6.48
-36.97
-85.09%
NKTX
Nkarta
2.29
0.28
13.93%
CCCC
C4 Therapeutics
3.64
1.06
41.09%
STTK
Shattuck Labs
7.16
6.38
817.95%
NVCT
Nuvectis Pharma
18.83
12.66
205.19%
ACTU
Actuate Therapeutics, Inc.
1.23
-6.84
-84.76%
Tevogen Bio Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and Compliance
Tevogen Bio Holdings Rebrands as Tevogen Inc.
Neutral
Jul 30, 2026
On July 29, 2026, Tevogen Bio Holdings Inc. filed a certificate of amendment to change its corporate name to Tevogen Inc., with the new name becoming effective on July 30, 2026. In tandem, the board approved a related bylaws amendment to reflect t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.